What Perdofemina Treats: Main Uses and Benefits

Perdofemina, which contains the active ingredient ibuprofen lysinate, is applied across domains where additional symptomatic support is needed. This medication is commonly used to help with symptoms related to physical discomfort, systemic imbalance, and inflammatory states, generally supporting symptomatic relief.

Easing Discomfort from Common Aches and Headaches

This domain assists with managing symptoms related to increased neurological or muscular activity, such as various headaches, muscle aches, and general back pain. It provides support that helps ease the overall symptom burden of common, recurrent pain episodes that may interfere with daily functioning. It is applied in situations where supportive pain assistance is sought.

Relief from Fever and Flu-Like Symptoms

The medication is relevant in contexts involving heightened systemic burden, specifically where fever and body aches occur together, such as during the common cold or flu-like symptoms. It contributes to easing the overall symptom load by addressing both the high temperature and the associated physical discomfort, supporting general well-being during symptomatic phases.

Targeted Relief for Inflammation and Episodic Pain

Applied in conditions involving inflammatory or irritative processes, this use is relevant for easing localized swelling and pain following minor soft tissue issues or dental procedures. It is also commonly used to help with the acute, episodic manifestations of conditions like primary dysmenorrhea (menstrual cramps) and may be part of symptomatic management for rheumatic disorders. This application assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive management for symptoms Perdofemina supports the patient during episodes of heightened discomfort by easing symptoms related to conditions involving inflammatory or irritative processes, such as minor sprains or the joint tenderness associated with rheumatic disorders.

Regulatory References

1. NIH MedlinePlus overview of Ibuprofen uses

The eligibility profile for Perdofemina is defined by official governmental regulations concerning its active ingredient, Ibuprofen, an NSAID. Use is generally established for Adults and Adolescents 12 years of age and older (and over 40 kg). The tablet formulation is not intended for use in children younger than 12.

The medicine is absolutely contraindicated in patients with a known hypersensitivity to aspirin or other NSAIDs, those with an active or history of recurrent peptic ulcer/haemorrhage, or a history of GI bleeding related to previous NSAID therapy. It must also not be used in patients with Severe Heart Failure (NYHA Class IV), Severe Renal or Hepatic Failure, or during the third trimester of pregnancy.

Restricted Use and Caution is required for patients with mild to moderate organ impairment, uncontrolled hypertension, established cardiovascular disease, pre-existing asthma, Inflammatory Bowel Disease, or Systemic Lupus Erythematosus (SLE). During the first and second trimesters of pregnancy, use is not recommended unless clearly necessary, though it poses minimal risk to the infant during breastfeeding.

Interactions with other medicines and products

The interaction profile of this medicine (Ibuprofen) is structured around official regulatory findings concerning pharmacodynamic and clearance effects of co-administered substances.

Contraindicated and High-Risk Combinations

Co-administration with other NSAIDs, including COX-2 selective inhibitors, is formally prohibited due to a documented significant increase in the risk of gastrointestinal bleeding and ulceration. Concomitant use with Anticoagulants (e.g., Warfarin), Oral Corticosteroids, and SSRIs may enhance the documented risk of severe hemorrhage or bleeding events.

Altered Drug Clearance and Exposure

The regulatory profile documents that this medicine can reduce the renal clearance of substances such as Lithium and Methotrexate, which may lead to a potential increase in their plasma concentrations. The medicine may also diminish the therapeutic effects of Antihypertensives and Diuretics and carries an increased risk of nephrotoxicity when administered alongside immunosuppressants like Ciclosporin.

Timing and Non-Drug Constraints

Specific temporal constraints apply to certain combinations: regulatory guidance advises administering the medicine at least 8 hours before or 30 minutes after immediate-release, low-dose Aspirin to avoid interference with its antiplatelet effect. Additionally, the risk of gastrointestinal bleeding is formally documented to increase with daily Alcohol consumption (three or more drinks). Interaction severity is also noted to be higher in Elderly Patients.

The mechanism of action for Perdofemina is defined by the selective biological activity of its active ingredient, ibuprofen, optimized for speed by the lysinate salt formulation. The core action is the reversible competitive inhibition of both the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By blocking the active sites, ibuprofen prevents the conversion of arachidonic acid into prostaglandins, which are critical lipid mediators. This enzymatic blockade reduces the synthesis rate of these mediators, disrupting the downstream signaling cascade associated with nociception and inflammatory responses. The systemic physiological consequences include altered signaling dynamics in the hypothalamus, leading to a reset of the elevated core thermoregulatory set-point, and reduced chemical sensitization of peripheral nociceptors in injured tissue. The mechanism is constrained by its reversible nature and its limitation to the eicosanoid pathway, sparing the Lipoxygenase pathway.

How to Take Perdofemina (Ibuprofen Lysinate) - Official Instructions

Perdofemina is an orally administered medication containing Ibuprofen Lysinate, equivalent to 400 mg of Ibuprofen. Proper use must strictly adhere to the established instructions to ensure safety and effectiveness.

Administration Details

Special Procedural Rules

• Preparation: The tablets must be swallowed whole with a glass of water and should not be crushed, chewed, or divided unless the specific tablet formulation is scored for division.
• Age-Group Use: The medication is indicated for use in adults and adolescents aged 12 years and above (weighing 40 kg). Dosing for children under 12 years of age must be managed by a healthcare professional based on body weight.
• Maximum Daily Dose: The total daily intake must not exceed 1200 mg (three 400 mg tablets) within a 24-hour period for standard use.
• Missed Dose: If a patient misses a dose, they should take the next dose only when it is due, maintaining the minimum 4-hour interval between doses. Do not take a double dose to compensate for the missed one.

Summary of Protocol

The established protocol requires a single tablet to be taken up to three times daily, separated by a minimum of four hours. This structured, intermittent approach, coupled with the clear maximum daily dose limit, defines the usage pattern for patients managing their condition.

Research Evidence / Overview of Studies for Perdofemina

Evidence for Acute Pain and Fever Management

The active ingredient in Perdofemina was studied for its role in examining outcomes related to physical discomfort and systemic imbalance, such as fever. These investigations rely on short-term, randomized controlled trials (RCTs) and systematic reviews, where researchers measured the change in pain scores and body temperature. Studies reported group patterns related to the time it took for outcomes to appear and the overall duration of observed effects. Despite this, long-term effects are not fully established, as follow-up durations were typically limited to single-dose observations.

Evidence for Episodic Pain (Primary Dysmenorrhea)

Research evaluating this medicine for primary dysmenorrhea includes systematic reviews of RCTs. These trials explored outcomes reflecting daily functioning and patient-reported discomfort during acute phases of the menstrual cycle. Studies reported measured differences in pain scores when observed against a control. However, follow-up durations were limited, typically evaluating responses over single cycles. Consequently, long-term effects for continuous use across many years are not fully established, and comparative evidence regarding the lysinate salt formulation is lacking.

Evidence for Localized Inflammatory Pain Models

The evidence base for acute localized pain, such as pain following dental procedures, is derived from single-dose, placebo-controlled trials. Studies focused on outcomes linked to inflammatory states, noting patterns related to measured changes and the recorded time to the onset of the measured effect within the first few hours post-dose. The research limitation frames indicate that results apply only to the populations studied, meaning these findings may not be generalizable to all forms of acute musculoskeletal pain.

Duration, Special Populations, and Overall Uncertainty

The overall research landscape describes studies primarily relevant to short-term or episodic symptom patterns; extended research examining maintenance or durability is not the focus of existing controlled trials. Research has explored the medicine in pediatric populations for fever, examining outcomes against a control and in contexts where other active agents were studied. However, data for other groups, such as older adults with complex health profiles or certain comorbidity-defined groups, remain insufficient across the controlled trial setting. Research contributes to the broader evidence landscape, yet data for certain groups remain insufficient, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review
2. Guideline: Non-opioid medications for the management of acute dental pain in adolescents, adults, and older adults

Common questions about Perdofemina (FAQ)

Q: What is the main reason doctors or prescribers use Perdofemina for?

A: According to the official product information, this medicine is indicated for the symptomatic relief of mild to moderate pain, inflammation, and fever. This 'triple action' means it is authorized for various indications, including primary dysmenorrhea (menstrual pain) and general body aches. The research and regulatory summaries focus on these core therapeutic uses.

Q: How quickly does Perdofemina typically start working?

A: Studies and official information indicate that the active ingredient, Ibuprofen, typically begins to work within 20 to 30 minutes of being taken. The lysinate salt formulation is designed to enhance the medication's dissolution and absorption, supporting a rapid onset of the therapeutic effect.

Q: How long are the effects of one dose of Perdofemina supposed to last?

A: Official dosing guidelines set a minimum interval of four hours between doses. A single dose of the active ingredient typically provides effective pain relief for four to six hours, which is the expected duration of effect documented in clinical studies.

Q: Can Perdofemina be taken with other types of over-the-counter medication?

A: Regulatory documents strictly warn against combining this medicine with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). While combinations with other types of over-the-counter medicines (like acetaminophen) are generally not strictly prohibited, the assessment of specific combinations is best done by a healthcare professional.

Q: Are there any common foods or drinks that should be avoided when taking Perdofemina?

A: The official product information documents that the risk of gastrointestinal bleeding is increased when the medication is consumed alongside daily alcohol (three or more drinks). There are no specific food restrictions, though the drug is often advised to be taken after a meal to reduce the possibility of stomach discomfort.

Q: What does the research say about the effectiveness of Perdofemina?

A: Clinical trials and systematic reviews indicate that the active ingredient is effective in reducing symptoms of acute pain, inflammation, and fever when compared to a control group. The research contributes to the broader evidence base supporting its authorized uses.

Q: Why do some people experience stomach upset after taking Perdofemina?

A: As an NSAID, this medicine can cause gastrointestinal upset. This is related to its mechanism of action, which can disrupt the synthesis of protective substances in the stomach lining. For this reason, the product label suggests administration after a meal, particularly for individuals with a sensitive stomach.

Q: Is Perdofemina prescribed for conditions other than its main use?

A: The official indications state the product is authorized for the symptomatic relief of mild to moderate pain, inflammation, and fever. The authorized use covers specific conditions like primary dysmenorrhea, where its triple action is beneficial.

Q: Are there clinical trials available for public review for Perdofemina?

A: Yes, official regulatory documents confirm the clinical trials used for approval. The existence and availability of this data are typically maintained on public registries, such as the NIH's ClinicalTrials.gov or the EU Clinical Trials Register.

Q: Is Perdofemina known by any other name?

A: The active ingredient in this medicine is Ibuprofen Lysinate. This compound is marketed under various brand names across different global markets, in addition to being available as generic Ibuprofen.

Q: Does Perdofemina contain any hormones?

A: No, the active ingredient is Ibuprofen Lysinate, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This class of medicine is not hormonal.

Q: Does Perdofemina have any known interactions with birth control pills?

A: Official warnings do not typically highlight a specific, critical interaction between ibuprofen and common oral contraceptives. However, regulatory information advises caution regarding other hormonal agents and effects on fertility, and the assessment of specific combinations is best done by a healthcare professional.

Q: Can people who are allergic to certain antibiotics still use Perdofemina?

A: The absolute contraindication for this medicine is specifically for a known hypersensitivity to aspirin or other NSAIDs. An allergy to an antibiotic does not automatically prevent use, but official guidance notes that caution is necessary for individuals with any known drug hypersensitivity.

Q: Does Perdofemina cause changes in weight?

A: Weight change is not listed as a common direct side effect. However, official warnings for NSAIDs do document that certain adverse reactions, related to fluid retention, can rarely include rapid weight gain.

Q: Is Perdofemina known to interact with herbal supplements?

A: Regulatory agencies note that caution is warranted regarding co-administration with herbal supplements that possess antiplatelet (blood thinning) activity, such as Ginkgo or Ginger, due to a potential increased risk of bleeding.

Q: Is Perdofemina a narcotic or controlled substance?

A: No, the active ingredient, Ibuprofen Lysinate, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not designated as a narcotic or controlled substance by government health authorities.

Q: Is it okay to drive or operate machinery while taking Perdofemina?

A: The official label states that the medicine may cause certain documented side effects, such as dizziness or drowsiness (lethargy/insomnia). These effects may impair a person's ability to drive or operate machinery, caution is therefore warranted.

Q: Is Perdofemina available over the counter, or is a prescription required?

A: The active ingredient, Ibuprofen, is available in two main regulatory categories: lower strengths are typically sold over-the-counter (OTC), and higher strengths require a prescription. The status depends on the specific product formulation and national regulatory approval.

Q: How long does Perdofemina stay in your system after you stop taking it?

A: Pharmacokinetic data indicates that the active ingredient has an elimination half-life of approximately 1.8 to 2.5 hours in healthy adults. It is generally eliminated from the system within 10 to 12 hours after the last dose is taken.

Q: Does Perdofemina impact mood or cause anxiety?

A: Some documented adverse effects, though typically uncommon, include central nervous system (CNS) effects. These effects may involve changes such as anxiety, agitation, and nervousness, as listed in the regulatory safety profile.

Q: Is there a generic version of Perdofemina?

A: Yes, as the active ingredient is Ibuprofen Lysinate, a widely known compound, various generic and branded versions containing the same active substance are available globally.

Q: What is the definition of a 'contraindication' for Perdofemina?

A: A contraindication is a fundamental factor or pre-existing medical condition (such as severe heart, liver, or kidney failure) that regulatory authorities deem an absolute reason to withhold a particular treatment because it may be harmful or life-threatening.

Q: How is Perdofemina eliminated from the body?

A: Official pharmacological data indicates that the active ingredient is primarily metabolized (broken down) in the liver. It is then mostly excreted from the body via the urine as inactive metabolites.

Q: Can Perdofemina be taken by someone with diabetes?

A: Regulatory guidance notes that caution is warranted for patients with certain pre-existing conditions, including diabetes, especially when the medicine is used at higher doses or for an extended duration. The assessment of use in such cases is best done by a healthcare professional.

Q: What is the difference between an allergy and a side effect of Perdofemina?

A: A side effect is a known, non-immune reaction often related to the drug's mechanism (e.g., stomach upset). An allergy is an immune system reaction that mistakenly identifies the drug as a foreign threat, leading to potentially severe symptoms (e.g., difficulty breathing, severe rash) which are clinically classified as emergencies.

How to Store and Dispose of Perdofemina

Perdofemina (ibuprofen lysinate) must be stored and handled in strict accordance with the medicine's official regulatory labeling to ensure stability and public safety.

Storage and Protection Requirements

Disposal Instructions

Official guidelines require that unused or expired Perdofemina be disposed of in accordance with local regulations. The product should not be flushed down the toilet or released into drains, waterways, or soil. If a drug take-back program is unavailable, follow standard household trash disposal methods for non-flushable medicines by mixing them with an undesirable substance.